Search

Your search keyword '"Selva-Nayagam, Sudarsha"' showing total 10 results
Start Over Author "Selva-Nayagam, Sudarsha"
10 results on '"Selva-Nayagam, Sudarsha"'

2. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Zola, Paolo, Casanova, Claudia, Arcangeli, Valentina, Antonuzzo, Lorenzo, Gadducci, Angiolo, Cosio, Stefania, Clamp, Andrew, Persic, Mojca, McNeish, Ian, Tookman, Laura, Redondo Sanchez, Andrés, Choi, Chel Hun, Baldini, Editta, Palaia, Innocenza, Benedetti Panici, Pierluigi, Takahashi, Nobutaka, Lombard, Janine, Ardizzoia, Antonio, Bologna, Alessandra, Herrero Ibáñez, Ana Maria, Musolino, Antonino, Márquez Vázquez, Raúl, Pietzner, Klaus, Braicu, Elena, Heinzelmann-Schwarz, Viola A., Powell, Melanie, Yokoyama, Yoshihito, Baron-Hay, Sally, Abeni, Chiara, Martin Lorente, Cristina, Cueva, Juan Fernando, Trillsch, Fabian, Heitz, Florian, Ataseven, Beyhan, Petru, Edgar, Heubner, MartinLeonhard, Sadozye, Azmat Hassanq, Dubey, Sidharth, Tazbirkova, Andrea, Tiley, Susan, Chrystal, Kathryn, Kim, Sang Wun, Fehr, Mathias, Scatchard, Kate, Anand, Anjana, Taylor, Alexandra, Watary, Hidemichi, Enomoto, Takayuki, Yoshihara, Kosuke, Selva-Nayagam, Sudarsha, Karki, Bhaskar, Harrison, Michelle, Wilkinson, Kate, Goh, Jeffrey, Glasgow, Amanda, Chantrill, Lorraine, Lee, Chulmin, Bertolini, Alessandro, Narducci, Filomena, Bellotti, Giovanna, Fusco, Vittorio, Aebi, Stefan, Del Grande, Maria, Colombo, Ilaria, Tokunaga, Hideki, Shigeta, Shogo, Goss, Geraldine, Siow, Zhen Rong, Steer, Christopher, Lin, Hao, Lee, Kwang-Beom, Di Meglio, Giovanni, Massa, Elena, De Marino, Elvira, Tortora, Vincenzo, Palacio Vazquez, Isabel, Tsuji, Kosuke, Tominaga, Eiichiro, Black, Allison, So, Kyeong A, Suh, Dong Hoon, Lee, Keun Ho, Kim, Yong Man, Fossati, Roldano, Carlucci, Luciano, Barberis, Massimo, Torri, Valter, Santoni, Anna, Colombo, Nicoletta, Biagioli, Elena, Harano, Kenichi, Galli, Francesca, Hudson, Emma, Antill, Yoland, Rabaglio, Manuela, Marmé, Frederic, Marth, Christian, Parma, Gabriella, Fariñas-Madrid, Lorena, Nishio, Shin, Allan, Karen, Lee, Yeh Chen, Piovano, Elisa, Pardo, Beatriz, Nakagawa, Satoshi, McQueen, John, Zamagni, Claudio, Manso, Luis, Takehara, Kazuhiro, Tasca, Giulia, Ferrero, Annamaria, Tognon, Germana, Lissoni, Andrea Alberto, Petrella, Mariacristina, Laudani, Maria Elena, Rulli, Eliana, Uggeri, Sara, and Barretina Ginesta, M Pilar

Published
2024
Full Text
View/download PDF

7. Personalized total neoadjuvant therapy (pTNT) for advanced rectal cancer with tailored treatment sequencing based on clinical stage at presentation.

Author

Bedrikovetski, Sergei, Fitzsimmons, Tracy, Perry, Joanne, Vather, Ryash, Carruthers, Scott, Selva-Nayagam, Sudarsha, Thomas, Michelle L., Moore, James W., and Sammour, Tarik

Subjects
RECTAL cancer, NEOADJUVANT chemotherapy, CANCER treatment, SYMPTOMS, CONSOLIDATION chemotherapy, INDUCTION chemotherapy
Abstract

Background: This study aimed to assess short-term outcomes of a personalized total neoadjuvant treatment (pTNT) protocol, with treatment sequencing based on clinical stage at presentation. Methods: A multidisciplinary pTNT protocol was implemented across two metropolitan hospitals. This consists of two-schema based on clinical stage: patients with distant failure risk were offered induction chemotherapy before chemoradiation (nCRT), and patients with locoregional failure risk received nCRT followed by consolidation chemotherapy. Patients underwent surgical resection unless a complete clinical response (cCR) was achieved, in which case non-operative management (NOM) was offered. A prospective cohort analysis of all patients with rectal cancer who underwent pTNT with curative intent between Jan 2019 and Aug 2022 was performed. Results: Of 270 patients referred with rectal cancer, 102 received pTNT with curative intent and 79 have completed their treatment thus far. Thirty-three patients (41.8%) received induction chemotherapy and 46 (58.2%) received consolidation chemotherapy per protocol. The percentage of patients with EMVI, resectable M1 disease, cT4 disease, and positive lateral lymph nodes were 54.4%, 36.7%, 27.8% and 15.2%, respectively. Overall, 32 (40.5%) patients had cCR and 4 (5.1%) pCR, and 40 (50.6%) patients had non-operative management. Grade 3 toxicity was reported in 10.1% of patients and only three patients (3.8%) experienced Grade 4 chemotherapy-related toxicity, with no treatment related mortality. Conclusion: Early results with a defined two-schema pTNT protocol are encouraging and suggest that tailoring sequencing to disease risk at presentation may represent the optimal balance between local and distant disease control, as well as treatment toxicity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Cancers of the corpus uteri treated in South Australian public hospitals: Trends in clinical management and survival across three decades

Author

Roder, David, primary, Selva‐Nayagam, Sudarsha, additional, Paramasivam, Sellvakumaran, additional, Keefe, Dorothy, additional, Olver, Ian, additional, Miller, Caroline, additional, Buckley, Elizabeth, additional, Powell, Kate, additional, Fusco, Kellie, additional, Buranyi‐Trevarton, Dianne, additional, and Oehler, Martin, additional

Published
2020
Full Text
View/download PDF

9. The impact of breast cancer on fears of exercise and exercise identity

Author

James Murray, Rebecca Perry, Emma Pontifex, Sudarsha Selva-Nayagam, Eva Bezak, Hunter Bennett, Murray, James, Perry, Rebeca, Pontifex, Emma, Selva-Nayagam, Sudarsha, Bezak, Eva, and Bennett, Hunter

Subjects
psychosocial, Surveys and Questionnaires, Humans, physical activity, Breast Neoplasms, Female, General Medicine, Fear, breast carcinoma, questionnaires, Exercise
Abstract

Objectives: Low exercise adherence is common amongst breast cancer (BC) patients. This study aimed to understand BC patients exercise identity and fears of exercise to identify barriers to exercise participation. Methods: Women (18 years plus) currently undergoing, or completed (in remission), chemotherapy for BC, and women (18 years plus) with no cancer history completed three validated questionnaires: Exercise Identity Scale (EI), Exercise Fear Avoidance Scale (EFAS) and Fear of Physical Activity/Exercise Scale – Breast Cancer. Results: 86 women were included (BC: n = 51 – non-cancer: n = 35). There were no significant differences between groups when comparing overall EI (p = 0.240; d=0.127) and EFAS (p = 0.060; d=0.203) scores. BC reported significantly higher scores on specific questions related to fear during exercise (EFAS 2,3, and 5; p =

Published
2022

10. Cancers of the corpus uteri treated in South Australian public hospitals: Trends in clinical management and survival across three decades

Author

Ian N. Olver, Dorothy M. K. Keefe, Sellvakumaran Paramasivam, Martin K. Oehler, Elizabeth Buckley, Dianne Buranyi-Trevarton, Sudarsha Selva-Nayagam, Kellie Fusco, David Roder, Kate Powell, Caroline Miller, Roder, David, Selva-Nayagam, Sudarsha, Paramasivam, Sellvakumaran, Keefe, Dorothy, Olver, Ian, Miller, Caroline, Buckley, Elizabeth, Powell, Kate, Fusco, Kellie, Buranyi-Trevarton, Dianne, and Oehler, Martin

Subjects
medicine.medical_specialty, medicine.medical_treatment, Population, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Neoplasms, South Australia, medicine, Humans, Clinical registry, Registries, education, Neoplasm Staging, Aged, 80 and over, Chemotherapy, education.field_of_study, business.industry, Hospitals, Public, Hazard ratio, Uterus, Australia, Infant, Newborn, Cancer, medicine.disease, Radiation therapy, Oncology, 030220 oncology & carcinogenesis, Female, Hormone therapy, business, Corpus Uteri
Abstract

Objective: To investigate treatment and survival over three decades. Methods: Clinical registry data from three major public hospitals analysed using Kaplan–Meier product-limit estimates and multivariate proportional hazard regression to determine disease-specific survival. Results: Five-year survival increased from 75% to 84%. The adjusted hazard ratio (HR, 95% CI) was 0.56 (0.41, 0.77) for 2010–2016 compared with 1984–1989 and was higher for: ages 80+ years; more advanced stages; poorly differentiated tumours; and complex mixed epithelial and mesenchymal tumours and sarcomas. Treatment was by surgery (92%), radiotherapy (33%), chemotherapy (12%) and hormone therapy (10%). Adjusted analyses showed radiotherapy and hormone therapy were less common from 1990 and chemotherapy more common for 2010–2016. Treatment likelihood was lower for ages ≥80 years, mixed epithelial and mesenchymal tumours receiving surgery and chemotherapy, but higher for radiotherapy. Advanced cancers (FIGO stage IV) had less surgery but more non-surgical treatments. Marginal evidence presented of more hormone therapy for high socio-economic areas. Conclusions: Survival was equivalent to national figures for Australia and the United States, but potentially higher than for England and Wales. Cases aged 80+ years had less care and poorer survival. Findings illustrate the complementary roles of hospital and population-based registries in local service evaluation Refereed/Peer-reviewed

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results